# E-DRUG: Re: Dipyrone **URL:** https://talk.edrugplus.org/t/e-drug-re-dipyrone/3184 **Category:** e-drug **Created:** [July 30, 1998, 5:53pm UTC](https://talk.edrugplus.org/t/e-drug-re-dipyrone/3184 "1998-07-30T17:53:08Z") **Posts on this page:** 1 **Page:** 1
### Author: ![cdf](https://avatars.discourse-cdn.com/v4/letter/c/9de053/32.png) [@cdf](https://talk.edrugplus.org/u/cdf) #### Post date: [July 30, 1998, 5:53pm UTC](https://talk.edrugplus.org/t/e-drug-re-dipyrone/3184/1 "1998-07-30T17:53:08Z")
E-drug: Re: Dipyrone ---------------------------------------------------------- The data we offered about dipyrone and % of agranulocytosis due to this drug were given in a Lecture by Dr Joan-Ramon Laporte in December 1996, in Institut Catala de Farmacologia. This Centre is the coordinator for Barcelona in the Boston Study. I would like to know which analgesics are more effective, harmless and cheaper than dipyrone with exception of ibuprofen, which is currently known as the NSAID with better relation benefit/risk. We must remember that Hartl (Excerpta Medica Monogr,147,1976) established in 1964 that the incidence of agranulocytosis type I was 0,8% for USA, but this conclusion was made from Huguley's data (JAMA, 1964, 188:817, JAMA 1964,189:938-41) and Discombe (BMJ, 1952,1:1270-73) At the same time Discombe cited data from other authors which used mainly aminopyrine. This data have been widely applied to Dipyrone and USA population. In a monograph by Prof. Geraldo Halfeld, a Brazilian academic, mortality is analysed, as well as per capita use of dipyrone in 1976; it was observed the mean mortality of countries that use dipyrone is 0,61 x 100 000 inhabitants and in countries which DO NOT USE dipyrone is 0,68 x 100 000. Sweden and Australia reintroduced it after having banned it, and agranulocytosis incidence kept the same. Even though the Boston Study has been critized, I don't know of another reliable study. In this study the incidence for agranulocytosis due to dipyrone is 0.0002% related to all analgesics, which is considered very low. We do not deny dipyrone produces agranulocytosis, but we do say it's not in an elevated degree as to banish its use and deprive the population of a drug with so good ratio benefit/risk. We quietly accept high incidence of gastrointestinal bleeding by ASA, with a letality of 10 - 20 % (BMJ1973;3:655), though less mortality has been reported, but not for this reason has been banished. The data offered by Dr Pablo Adolfo Elios are very interesting, in Buenos Aires population, which seems to have a great incidence of agranulocytosis and is in agreement with other authors such as Larrinaga (Medicina, B. Aires 1994, 54:13-6). Probably the Argentine population has increased sensitivity for suffering agranulocytosis, which might be due to more use of dipyrone or geographical risk variations (Levy,M Agent Actions suppl 1988,25:21-31) I consider the exchange of ideas has been very valuable Best regards to all participants CENTRO PARA EL DESARROLLO DE LA FARMACOEPIDEMIOLOGIA Dr Juan A Furones, Senior Lecturer on Pharmacology, MD Rogelio Fernandez, Pharmacist, PhD Frank Debesa, Pharmacist B Sc Pharmacoepidemiology Development Center 44 No 502 esq 5a Ave Miramar, Playa Havana, Cuba CP 11300 E-mail; cdf@infomed.sld.cu FAX: (537)24-7227 Phone(537) 24-0924 -- Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'. Mail administrative requests to `majordomo@usa.healthnet.org'. For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.